In February 2005, Syrrx merged with Takeda Pharmaceutical Company [Japan], a developer, manufacturer, and marketer of a broad range of pharmaceutical product. Now doing business as as Takeda San Diego, the firm is a drug discovery company committed to redefining the way medicines are discovered. At the forefront of rational drug discovery, Syrrx leverages high-throughput structural biology, high-throughput screening, combinational and medicinal chemistry together with computational methods to discover small molecule drugs to address unmet medical needs. Syrrx achieves a competitive advantage in drug discovery by leveraging its leading high-throughput X-ray crystallography capabilities to determine the three dimensional structures of drug targets. Syrrx uses these structures to efficiently design best-in-class drug candidates. Syrrx directs its efforts toward therapeutics to treat metabolic diseases, cancer, and inflammation, and has multiple R&D pipeline products including several compounds directed to type 2 diabetes already in clinical development. Syrrx will become a subsidiary of Takeda America Holdings, a wholly owned subsidiary of Takeda. This merger will integrate Syrrx's technologies and R&D pipeline into Takeda and establish a discovery research presence for Takeda in the US. This relationship is expected to help Takeda further enhance its R&D pipeline and to create more drugs as early as possible through efficient discovery processes including identification of target molecules, search for hit compounds, and medicinal chemistry research. Syrrx will become part of Takeda's global discovery research network together with Takeda's existing discovery centers in Osaka and Tsukuba, Japan.
